comparemela.com

Latest Breaking News On - Long focus capital management - Page 2 : comparemela.com

Fund 1 Investments, Llc Acquires 25,000 Shares of Tilly s, Inc (NYSE:TLYS) Stock

Fund 1 Investments, Llc Acquires 25,000 Shares of Tilly s, Inc (NYSE:TLYS) Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Azul (NYSE:AZUL) Shares Gap Down to $10 24

Shares of Azul S.A. (NYSE:AZUL – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $10.24, but opened at $10.02. Azul shares last traded at $9.97, with a volume of 268,851 shares changing hands. Analyst Upgrades and Downgrades Several equities research analysts have recently weighed in […]

Brokerages Set FREYR Battery (NYSE:FREY) Target Price at $7 78

Shares of FREYR Battery (NYSE:FREY – Get Free Report) have been assigned a consensus recommendation of “Reduce” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month price […]

Insmed Incorporated (NASDAQ:INSM) Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lowered its holdings in Insmed Incorporated (NASDAQ:INSM – Free Report) by 2.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,700,000 shares of the biopharmaceutical company’s stock after selling 37,500 shares during the quarter. Hudson Bay Capital Management […]

Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Hold Rating from Analysts at StockNews com

StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a report published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock. ADAP has been the subject of several other reports. Barclays decreased their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.00 and set an […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.